Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,890)	$ (5,512)	$ (1,623)	$ (6,528)	$ (28,982)	$ (16,048)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	26		2		28	4
Amortization of operating right of use assets					15	0
Stock-based compensation					147	443
Common Stock issued in exchange for services					600	37
Change in fair value of warrant liabilities	4,963		(165)		8,481	(174)
Change in fair value of convertible promissory notes					8,032	(1,011)
Loss on convertible note conversions	772		127		4,239	127
Gain on exercise of warrant liabilities	(5,369)		0		(5,369)	0
Loss on issuance of registered direct Common Stock					730	0
Loss on consideration shares and warrants	0		0		1,277	0
Expense for debt issuance costs due to fair value election on Anson Notes					350	521
Warrant issuance costs related to Alvogen termination					0	1,336
Convertible note default penalty	0		0		0	849
Changes in operating assets and liabilities:
Prepaid expense and other assets					414	(100)
Account receivable					12	0
Accounts payable					100	4,949
Insurance loan payable					0	634
Operating lease liabilities					(63)	0
Accrued expense and other liabilities					(412)	(106)
Net cash used in operating activities					(10,399)	(8,539)
CASH FLOWS FROM INVESTING ACTIVITIES
Business acquisition, net of cash acquired					(2,561)	0
Net cash used in investing activities					(2,561)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of convertible note					0	(4,800)
Repayment of insurance note					(394)	0
Expense for debt issuance costs due to fair value election on Anson Notes					(350)	(521)
Proceeds from issuance of insurance loan					227	0
Proceeds from Anson convertible note, net					5,000	2,941
Proceeds from liability classified warrants					0	2,059
ATM offering, net of offering costs					4,751	0
Proceeds from issuance of Common Stock and warrants issued in private placement, net of issuance costs					0	1,027
Net cash provided by financing activities					18,701	5,590
Net increase (decrease) in cash and cash equivalents					5,741	(2,949)
Cash and cash equivalents at beginning of period		$ 1,443		$ 4,595	1,443	4,595	$ 4,595
Cash and cash equivalents at end of period	$ 7,184		$ 1,646		7,184	1,646	$ 1,443
Supplemental disclosure of cash flow information:
Cash paid for interest					374	374
Cash paid for taxes					0	0
Non-cash investing and financing activities:
Issuance of Common Stock warrants as offering costs					0	188
Exercise of the warrants for subscription receivable					3,087	0
Amortization of deferred offering costs to additional paid-in capital					120	0
Conversion of Series A Preferred Stock to Common Stock [Member]
Non-cash investing and financing activities:
Conversion of Series A preferred stock into Common Stock					0	3
Conversion of Principal and Interest Into Common Stock [Member]
Non-cash investing and financing activities:
Issuance of Common Stock as principal and interest repayment for convertible notes					11,142	1,102
Consideration Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Common Stock and warrants, net of issuance costs					9,468	0
Warrants Other Than Consideration Warrants [Member]
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of Common Stock and warrants, net of issuance costs					$ 0	$ 4,884